EMA issues first paediatric use positive opinion
This article was originally published in SRA
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued its first ever positive opinion for paediatric use marketing authorisation (PUMA) under the new Paediatric Regulation that came into force in 20071.
You may also be interested in...
Just over a year ago, AstraZeneca at last returned to growth and set about a reorganization that placed oncology at the heart of its plans for continued success. In Vivo talked to the executive vice-president of its Oncology Business Unit David Fredrickson about how the company hopes to become a major cancer player.
The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.
Andrew McConaghie and Alex Shimmings are joined by John Hawkins, biographer of biotech pioneer Henri Termeer, and Idea Pharma's Mike Rea to pick out their personal book highlights of 2019.